Opinion|Videos|October 28, 2024
Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC
Key Takeaways
- Multidisciplinary teams should integrate oncologists and urologists, emphasizing patient-centered care for high-risk non–muscle-invasive bladder cancer.
- Global preparation involves understanding diverse market needs and ensuring access to resources and education.
Panelists discuss the characteristics of an ideal multidisciplinary team for managing BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), emphasizing the need for oncologists and urologists to collaboratively prepare for successful patient outcomes across different markets, while also identifying necessary educational resources and highlighting adverse events that require attention in preparation for product launches.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What does an ideal multidisciplinary team look like in BCG-naive, high-risk non–muscle-invasive bladder cancer? How can the team (oncologists & urologists) prepare globally (in different markets) to set up patients for the most success?
- What education or resources are needed prior to the launch of these products or prior to this evolving landscape to prepare for the launches?
- What adverse events need attention and education as part of the prelaunch preparation?
- Closing thoughts from each of the panelists.
Advertisement
Related to this article
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants fast track designation to pre-biopsy 68Ga-PSMA-PET program
2
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
3
Brian Mazzarella, MD, reviews early data on water vapor therapy for localized prostate cancer
4
Pivotal trial launches of GRPR-targeted PET imaging agent in prostate cancer
5